Detection and monitoring of clonality in peripheral blood and bone marrow of patients with B-cell lymphoproliferative disorders

Hematological Oncology

Volumn 21, Issue 1, 2003, Pages 25-31

  Leal, E ^a   Esparza Flores, M A ^b   Lopez Guido B ^b   Aguilar Luna, C ^b   Aguilar Lopez L ^c   Jaloma Cruz, A R ^a   Medina, C ^a   Barros Núñez, Patricio ^a,d  

^a Ctro Invest Biomedica Occidente   (Mexico)

^b HOSPITAL DE PEDIATRÍA   (Mexico)

^c HOSPITAL DE ESPECIALIDADES   (Mexico)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA DE OCCIDENTE   (Mexico)

Author keywords

CDR3; Clonality; IgH rearrangements; Leukemia; Lymphoproliferative

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN;

B LYMPHOCYTE; BLOOD; BONE MARROW; CELL MATURATION; GENE; HUMAN; LYMPHATIC LEUKEMIA; LYMPHOCYTE CLONE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW;

B-LYMPHOCYTES; BONE MARROW CELLS; CLONE CELLS; COMPLEMENTARITY DETERMINING REGIONS; FUSION PROTEINS, BCR-ABL; GENE REARRANGEMENT; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; POLYMERASE CHAIN REACTION; RECURRENCE; TIME FACTORS;

EID: 0037344115     PISSN: 02780232     EISSN: None     Source Type: Journal    
DOI: 10.1002/hon.701     Document Type: Review

References (32)

1. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302: 575-581.
2. Yamada M, Hudson S, Tournay O, et al. Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementary determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA 1989; 86: 5123-5127.
3. Brisco MJ, Tan LW, Orsbom AM, Morley AA. Development of a highly sensitive assay, based on the polymerase chain reaction, for rare B-lymphocyte clones in a polyclonal population. Br J Haematol 1990; 75: 163-167.
4. Nizet Y, Martiat P, Vaerman JL, et al. Follow-up of residual disease (MRD) in B-lineage acute leukaemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol 1993; 79: 205-210.
5. Brisco MJ, Sykes PJ, Hughes E, et al. Monitoring minimal residual disease in peripheral blood in B-lineage acute lymphoblastic leukaemia. Br J Haematol 1997; 99: 314-319.
6. Oster W, Lindemann A, Mertelsmann R, Herrmann F. Minimal peripheral blood cells carrying clonal markers of B-cell disorders: evidence for monoclonality of circulating lymphocytes in patients with multiple myeloma. Int J Cell Cloning 1989; 7: 111-119.
7. Van Rhee F, Marks DI, Lin E, et al. Quantification of residual disease in Philadelphia-positive acute lymphoblastic leukemia: comparison of blood and bone marrow. Leukemia 1995; 9: 329-335.
8. Yocota S, Hansen-Hagge TE, Ludwing WD, et al. Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 1991; 77: 331-339.
9. Martin H, Atta J, Bruecher J, et al. In patients with BCR-ABL positive ALL CR peripheral blood contains less residual disease than bone marrow: implications for autologous BMT. Ann Hematol 1994; 68: 85-87.
10. Pollard P, Owen G, Wordwood M. PCR based immunogenotyping at the Ig heavy chain CDR3 locus: improvements in resolution. Br J Hematol 1993; 84: 169-171.
11. Boyum A. Separation of leucocytes from blood and bone marrow. Scand J Clin Lab Invest 1968; 21(Suppl. 97): 1-129.
12. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual (2nd edn). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989.
13. Quentin MR, Brisco MJ, Jhosua DJ, Brown R, Gibson J, Morley AA. Advancement of multiple myeloma from diagnosis through plateau phase of progression does not involves a new B-cell clone: evidence from the Ig heavy chain gene. Blood 1993; 82: 202-206.
14. Potter MN, Steward CG, Maitland N, Oakhill A. Detection of clonality in childhood B-lineage acute lymphoblastic leukemia by the polymerase chain reaction. Leukemia 1992; 6: 289-294.
15. Sykes PJ, Snell LE, Brisco MJ, et al. The use of monoclonal gene rearrangement for detection of minimal residual disease in acute lymphoblastic leukemia of childhood. Leukemia 1997; 11: 153-158.
16. Stass S, Mirror J, Melvin S, Pui CH, Murphy SB, William D. Lineage switch in acute leukemia. Blood 1984; 64: 701-706.
17. Wright PJ, Poplack DG, Bakhshi A, et al. Gene rearrangements as markers of clonal variation and minimal residual disease in acute lymphoblastic leukemia. J Clin Oncol 1987; 5: 735-741.
18. Rivera GK, Raimondi SC, Hancock ML, et al. Improved outcome in childhood acute lymphoblastic leukemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.
19. Kuang S-Q, Gu L-J, Dong S, et al. Long-term follow-up of minimal residual disease in acute lymphoblastic leukemia patients by polymerase chain reaction analysis of multiple clone-specific or malignancy-specific gene markers. Cancer Genet Cytogenet 1996; 88: 110-117.
20. Green E, Conville CM, Powel JE, et al. Clonal diversity of Ig and T-cell receptor gene rearrangements identifies a subset of childhood B-precursor acute lymphoblastic leukemia with increased risk of relapse. Blood 1998; 92: 952-958.
21. Brisco MJ, Condon J, Hughes J, et al. Prognostic significance of detection of monoclonality in remission marrow in acute lymphoblastic leukemia in childhood. Australian and New Zealand Children's Cancer Study Group, Leukemia 1993; 10: 1514-1520.
22. Salo A, Pakkala S, Jansson SE, Helminen P, Palotie A. Monitoring of adult B-cell lineage acute lymphoblastic leukemia: validation of a simple method for detecting immunoglobulin heavy chain gene clonality. Leukemia 1993; 7: 1459-1465.
23. Kyodak K, Nakamura S, Matano S, Ohtake S, Matsuda T. Prognostic significance of immunoglobulin heavy chain gene rearrangement in patients with acute myelogenous leukemia. Leukemia 1997; 11: 803-806.
24. Schmetzer HM, Poleck B, Mittermuller J, Duell T, Wilmanns W, Gerhartz HH. Clonality analysis as a tool to study the biology and response to therapy in myelodysplastic syndromes. Leukemia 1997; 11: 660-666.
25. Macintyre EA, Delabesse E. Molecular approaches to the diagnosis and evaluation of lymphoid malignancies. Sem Hematol 1999; 36: 373-389.
26. Schmetzer HM, Poleck B, Duell T, Gerhartz HH, Mittermuller J. Cytogenetic and Southern blot analysis to demonstrate clonality and to estimate prognosis in patients with myelodysplastic syndromes. Ann Hematol 2000; 79: 20-29.
27. Dadej K, Gaboury L, Lamarre L, et al. The value of clonality in diagnosis and follow-up of patients with cutaneous T-cell infiltrates. Diag Mol Pathol 2001; 10: 78-88.
28. Raghavachar A, Thiel E, Bartram CR. Analysis of phenotype and genotype in acute lymphoblastic leukemias at presentation and relapse. Blood 1987; 6: 289-294.
29. Katz F, Ball L, Gibbons B, Chessels J. The use of DNA probes to monitor minimal residual disease in childhood acute lymphoblastic leukemia. Br J Haematol 1989; 73: 173-180.
30. Bunin NJ, Raimondi SC, Mirro J, Jr, Behm FG, Goorha R, Kitchingham GR. Alterations in immunoglobulin or T-cell receptor gene rearrangement at relapse: involvement of 11q23 and changes in immunophenotype. Leukemia 1990; 4: 722-731.
31. Frost L, Goodeve A, Wilson G, Peaket I, Barker H, Vora A. Clonal stability in late-relapsing childhood lymphoblastic leukemia. Br J Haematol 1997; 98: 992-994.
32. Beishuizen A, Verhoeven M-A, van Wering E, Hahlen K, Hoojikaas H, van Dongen J. Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 1994; 83: 2238-2247.